Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

Nitrosamines: USFDA issues guidance on R

USFDA: Recommended Acceptable Intake Limits for Nitrosamine Drug Substance[1]Related Impurities (NDSRIs) – Guidance for Industry

FDA approves Sage Therapeutics Zurzuvae

Zurzuvae (zuranolone), the first oral medication to treat postpartum depression (PPD) in adults. PPD is a

FDA published the fiscal year FY 2024 GD

The GDUFA fee rates show steepest increase for DMF by 21% to $94,682 from $78,293.

Intas, India issued USFDA Warning letter

Intas facility was inspected by FDA investigators Jose E Melendez, Justin A Boyd, Pratik S

Lupin recalls 4179 boxes of Drospirenone

Lupin recalls 4179 boxes of Tydemy. Tydemy is Drospirenone, Ethinyl Estradiol & Levomefolate Calcium Tablets

FDA Approves Tarsus’s Lotilaner (XDEMV

Tarsus Pharmaceuticals Inc., in a statement announced FDA approval of Lotilaner ophthalmology solution 0.25% (XDEMVYâ„¢).

FDA approves Cantharidin (YCANTH™,  V

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical

EMA updates Q&A document on N-Nitros

EMA updates Q&A document on N-Nitrosamines. In the Rev 16 (dated 7 July 2023) limits